What Temi does

Temi (operated by Self Systems, Inc., with clinical care delivered through Temi Medical Group) is a cash-pay, direct-to-consumer telehealth platform built around physician-prescribed GLP-1 weight-loss medications. Patients complete an online health questionnaire, receive asynchronous review from a licensed physician within 48 hours, and have prescriptions transmitted electronically to either a Temi mail-order pharmacy partner or a retail pharmacy of their choice. The platform currently operates in nine U.S. states (California, Texas, Florida, New York, Pennsylvania, Ohio, Michigan, North Carolina, Delaware), with a stated waitlist for additional states tied to physician licensure. The company is headquartered in Austin, TX, was founded in 2025, and is led by CEO Joshua Dong alongside Founding Clinical Partner Dr. Kevin Brandstetter, M.D.

The core product surface spans the $139/year Temi Care membership, prescription refill services ($15 or free with membership), a $79 new-medication prescription request, and $150 30-minute video visits. Medications include compounded semaglutide and tirzepatide (injectable and oral pill forms), as well as branded options — Wegovy, Zepbound, and the newly launched oral GLP-1 Foundayo (orforglipron). A core differentiator is pharmacy-direct pricing with Temi's markup capped at 15%, presented with side-by-side price comparison across partner pharmacies. Temi does not bill insurance and serves patients who are uninsured, underinsured, or simply prefer cash-pay to avoid prior authorization delays.

The business model combines subscription recurring revenue (annual membership), per-transaction prescription service fees, and capped transaction-based markup on medication costs. Go-to-market is exclusively online — content marketing through a medically reviewed blog, SEO-optimized medication pages, an eligibility quiz, and community testimonials via Reddit — with no enterprise or B2B channel. Operational compliance includes LegitScript certification, HIPAA-aligned data handling, and adherence to state telemedicine regulations through licensed physicians and a structured clinical entity.

Name

Temi

Legal name

Self Systems, Inc.

Website

https://usetemi.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Temi is a cash-pay, direct-to-consumer telehealth platform that connects patients with licensed physicians for asynchronous prescriptions of GLP-1 weight-loss medications (compounded and branded, including Foundayo, Wegovy, and Zepbound), operating across nine U.S. states via a $139/year membership and pharmacy-direct pricing.

Ownership category

akta.pro rank

Product category

Telehealth Weight Loss Services

NAICS

All Other Outpatient Care Centers (621498)

SIC

Services-Health Services (8000)

akta.pro primary industry

DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)

Keywords

• Telehealth services
• Weight loss medications
• GLP-1 prescriptions
• Online pharmacy platform
• Cash-pay healthcare

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Membership Fees: Annual Temi Care membership at $139/year provides prescription service, marketplace service on eligible orders, free refills, provider review, and 24/7 human support. Membership renews automatically annually.
2. Prescription Service Fees: Non-members pay $15 per prescription service. New medication requests cost $79. Video visits are $150 per 30-minute session with a licensed physician.
3. Medication Marketplace: Pharmacy-direct pricing with Temi markup capped at 15%. Non-members pay an additional 20% marketplace service on compounded medication orders. Revenue comes from the capped markup on medication costs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Temi operates a cash-pay telehealth platform that connects patients with licensed providers for asynchronous consultations to obtain GLP-1 weight loss medication prescriptions. The service includes online medical evaluations, prescription issuance, and an integrated pharmacy marketplace that allows patients to compare medication prices across partner pharmacies.

Product overview

Temi is a cash-pay telehealth platform offering doctor-prescribed GLP-1 weight loss medications. The core offering is the Temi Care membership ($139/year), which provides access to prescription services and waived surcharges on medications. The platform facilitates consultations with licensed physicians for compounded semaglutide and tirzepatide (injectable and oral forms), as well as branded options including Foundayo, Zepbound, and Wegovy. Additional services include video visits ($150), new medication prescription requests ($79), and medication refills ($15). All prescriptions require physician review before issuance. The platform connects patients with pharmacies for medication fulfillment, operating on a cash-pay basis without insurance billing.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Clinician reviews completed within 48 hours, often sooner
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature1 record

Partnerships

One partnership is on record.

• Mail-Order Pharmacy PartnerscoreOthersLicensed pharmacies that fulfill compounded semaglutide and tirzepatide prescriptions. Ships medication directly to patient homes. Patients can also choose pharmacy of their choice. Temi charges capped 15% markup on medication costs.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Ro: Private direct-to-consumer telehealth platform operating Ro Body for cash-pay GLP-1 weight loss with pharmacy-direct pricing and physician review. Comparable in clinical workflow, asynchronous review, and cash-pay pricing model to Temi.
• Calibrate: Cash-pay metabolic health and weight loss program combining clinician-prescribed GLP-1s with coaching. Comparable in clinical-prescription-plus-cash-pay model and focus on the same GLP-1-driven weight-loss patient segment.
• PlushCare: Telehealth provider offering online physician visits and prescription services including weight management, with pharmacy-direct fulfillment. Comparable in online physician-led prescribing and prescription-refill mechanics.
• Sesame: Cash-pay healthcare marketplace offering direct-to-consumer telehealth visits and prescription services including weight management. Comparable cash-pay, no-insurance-required positioning and transparent, pay-as-you-go pricing architecture.
• Found Health: DTC telehealth platform focused exclusively on weight loss with clinician-prescribed GLP-1 access. Closest single-vertical, cash-pay peer with similar content-and-quiz funnel and physician-led medication access.
• K Health: DTC telehealth platform offering weight management services including clinician-prescribed medications, on a cash-pay or membership basis. Comparable in async-first clinical model and direct-to-consumer online pharmacy access.
• Mochi Health: GLP-1-focused cash-pay telehealth provider combining clinician visits with pharmacy fulfillment. Highly comparable to Temi in product mix, async clinical model, and cash-pay positioning toward uninsured weight-loss patients.
• Hims & Hers Health: Public cash-pay telehealth platform (HIMS) offering direct-to-consumer GLP-1 weight loss alongside broader men's and women's health verticals. Closest analog to Temi in business model, pricing transparency stance, and subscription-plus-medication structure.

Broad incumbents

• Teladoc Health: Public broad telehealth incumbent (TDOC) with adjacent GLP-1 and chronic-condition offerings through acquired assets. Not a pure-play cash-play competitor, but its scale and breadth shape the competitive context in which Temi operates.

Emerging players

• Noom: Subscription weight-management platform with an emerging clinician-prescribed medication arm (Noom Med). Adjacent rather than direct: originally behavior-and-coaching, now layering the same GLP-1 telehealth workflow Temi is built around.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Temi